405 related articles for article (PubMed ID: 33488603)
1. Nanoparticle-Induced Complement Activation: Implications for Cancer Nanomedicine.
La-Beck NM; Islam MR; Markiewski MM
Front Immunol; 2020; 11():603039. PubMed ID: 33488603
[TBL] [Abstract][Full Text] [Related]
2. Cancer nanomedicine and the complement system activation paradigm: anaphylaxis and tumour growth.
Moghimi SM
J Control Release; 2014 Sep; 190():556-62. PubMed ID: 24746624
[TBL] [Abstract][Full Text] [Related]
3. Nanomedicine safety in preclinical and clinical development: focus on idiosyncratic injection/infusion reactions.
Moghimi SM
Drug Discov Today; 2018 May; 23(5):1034-1042. PubMed ID: 29146517
[TBL] [Abstract][Full Text] [Related]
4. Advanced targeted therapies in cancer: Drug nanocarriers, the future of chemotherapy.
Pérez-Herrero E; Fernández-Medarde A
Eur J Pharm Biopharm; 2015 Jun; 93():52-79. PubMed ID: 25813885
[TBL] [Abstract][Full Text] [Related]
5. Nanoparticle-Delivered Chemotherapy: Old Drugs in New Packages.
Lee MS; Dees EC; Wang AZ
Oncology (Williston Park); 2017 Mar; 31(3):198-208. PubMed ID: 28299757
[TBL] [Abstract][Full Text] [Related]
6. In Silico Models for Nanomedicine: Recent Developments.
Mascheroni P; Schrefler BA
Curr Med Chem; 2018; 25(34):4192-4207. PubMed ID: 28911299
[TBL] [Abstract][Full Text] [Related]
7. Nanoparticle-assisted combination therapies for effective cancer treatment.
Hu CM; Aryal S; Zhang L
Ther Deliv; 2010 Aug; 1(2):323-34. PubMed ID: 22816135
[TBL] [Abstract][Full Text] [Related]
8. Nanomedicines for cancer therapy: current status, challenges and future prospects.
Bor G; Mat Azmi ID; Yaghmur A
Ther Deliv; 2019 Feb; 10(2):113-132. PubMed ID: 30678550
[TBL] [Abstract][Full Text] [Related]
9. Factor H inhibits complement activation induced by liposomal and micellar drugs and the therapeutic antibody rituximab in vitro.
Mészáros T; Csincsi ÁI; Uzonyi B; Hebecker M; Fülöp TG; Erdei A; Szebeni J; Józsi M
Nanomedicine; 2016 May; 12(4):1023-1031. PubMed ID: 26733258
[TBL] [Abstract][Full Text] [Related]
10. Nanoscale drug delivery for targeted chemotherapy.
Xin Y; Huang Q; Tang JQ; Hou XY; Zhang P; Zhang LZ; Jiang G
Cancer Lett; 2016 Aug; 379(1):24-31. PubMed ID: 27235607
[TBL] [Abstract][Full Text] [Related]
11. Targeting liposomes toward novel pediatric anticancer therapeutics.
Federman N; Denny CT
Pediatr Res; 2010 May; 67(5):514-9. PubMed ID: 20118828
[TBL] [Abstract][Full Text] [Related]
12. Nanoparticle delivery strategies to target doxorubicin to tumor cells and reduce side effects.
Wang Y; Wei X; Zhang C; Zhang F; Liang W
Ther Deliv; 2010 Aug; 1(2):273-87. PubMed ID: 22816133
[TBL] [Abstract][Full Text] [Related]
13. Radiation effects on the tumor microenvironment: Implications for nanomedicine delivery.
Stapleton S; Jaffray D; Milosevic M
Adv Drug Deliv Rev; 2017 Jan; 109():119-130. PubMed ID: 27262923
[TBL] [Abstract][Full Text] [Related]
14. Drug delivery systems using polymer nanoassemblies for cancer treatment.
Bae Y
Ther Deliv; 2010 Sep; 1(3):361-3. PubMed ID: 22816139
[No Abstract] [Full Text] [Related]
15. The two directions of cancer nanomedicine.
Nat Nanotechnol; 2019 Dec; 14(12):1083. PubMed ID: 31802029
[No Abstract] [Full Text] [Related]
16. Factors Influencing the Delivery Efficiency of Cancer Nanomedicines.
Ullah R; Wazir J; Khan FU; Diallo MT; Ihsan AU; Mikrani R; Aquib M; Zhou X
AAPS PharmSciTech; 2020 May; 21(4):132. PubMed ID: 32409932
[TBL] [Abstract][Full Text] [Related]
17. Nanomedicine: An effective tool in cancer therapy.
Aftab S; Shah A; Nadhman A; Kurbanoglu S; Aysıl Ozkan S; Dionysiou DD; Shukla SS; Aminabhavi TM
Int J Pharm; 2018 Apr; 540(1-2):132-149. PubMed ID: 29427746
[TBL] [Abstract][Full Text] [Related]
18. Combining Nanomedicine and Immunotherapy.
Shi Y; Lammers T
Acc Chem Res; 2019 Jun; 52(6):1543-1554. PubMed ID: 31120725
[TBL] [Abstract][Full Text] [Related]
19. Tumor heterogeneity and nanoparticle-mediated tumor targeting: the importance of delivery system personalization.
Swetha KL; Roy A
Drug Deliv Transl Res; 2018 Oct; 8(5):1508-1526. PubMed ID: 30128797
[TBL] [Abstract][Full Text] [Related]
20. Nanomedicines Targeting the Tumor Microenvironment.
Tong R; Langer R
Cancer J; 2015; 21(4):314-21. PubMed ID: 26222084
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
